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Abstract
Background: PTEN is a tumor suppressor gene that regulates the PTEN/PI3k/AKT/mTOR pathway, which is
frequently altered in human cancers including gallbladder cancer (GBC). To determine the frequency of PTEN
expression in GBC and to establish its relation to clinical and morphological parameters and survival in GBC.
Methods: The immunohistochemical expression of PTEN was studied in 108 GBC. All the cases included areas of
non-tumor mucosa adjacent to the tumor.
Results: The group was comprised of 108 patients, 91 women (84.3 %) and 17 men (15.7 %) with an average age
of 65.2 years (SD ± 12.3 years). Thirty-five cases (33 %) were early carcinomas (EC) and the remaining 73 (67 %)
were advanced cases (AC). All the internal controls were positive (moderate or intense in 96.3 %). Only in three
AC (4.1 %) was there a complete absence of PTEN immunohistochemical expression. There were no significant
differences in relation between PTEN expression and tumor infiltration or degree of differentiation. The three
patients with PTEN inactivation died before 10 months; however, the other patients with AC had a survival of
53 % at 10 months.
Discussion: Loss of PTEN expression was observed in 4.1 % of the advanced GBC. All the patients with this
alteration died before 10 months. PTEN inactivation could be a rare event, but with a poor prognosis in
advanced GBC.
Background
For many years Chile has had the highest incidence and
mortality due to GBC in the world, in both genders,
and it represents the second cause of death by malig-
nant tumors in women in Chile [1–3]. Other Indo-
American countries like Bolivia, Mexico and Ecuador
follow in frequency, and in Asia countries such as India
and Pakistan [2, 4]. GBC ranks 20th among all malig-
nant tumors with an incidence of 2.2 × 106 inhabitants,
and 22nd for mortality (0.7 × 106) with a prevalence at
5 years of 16.8 × 106 inhabitants [2].
As with other epithelial malignant tumors, GBC is the
result of multiple genetic alterations involving multiple
genes from different metabolic pathways, the importance
of which has not yet been clearly established [5–9]. Nu-
merous somatic mutations have been reported for GBC,
of which only a small subgroup contributes to tumor
progression. The distinction has been made only re-
cently between mutations in the “driver” or controller
genes of the multiple mutations in neutral or “passen-
ger” genes that contribute in only a small way to cancer
development [10, 11]. The most frequently mutated
genes in GBC are TP53 (47.1 %), KRAS (7.8 %) and
ERBB3 (11.8 %) (https://www.sanger.ac.uk/). It has also
been shown recently that the signaling pathway of ErbB,
which includes EGFR, ERBB2, ERBB3 and ERBB4, is one
of the most frequently altered in GBC [12, 13].
PTEN (phosphatase and tensin homolog) is a tumor
suppressor gene located on chromosome 10q23. 3. PTEN
encodes a protein with a phosphatase function which, as it
removes phosphate groups, inactivates substrates and thus
acts as a tumor suppressor gene [9, 14]. The functional* Correspondence: ivanroaesterio@gmail.com
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loss of PTEN may be the result of somatic mutations, de-
letion or inactivation (LOH, methylation), abnormalities
in transcriptional and post-transcriptional regulation,
microRNAs, regulation of microRNAs, or due to alter-
ations in the mechanisms that regulate the stability and
degradation of the PTEN protein [15, 16]. The absence of
the functional protein PTEN enables unfettered PI3k
activity, which determines the uncontrolled production of
PIP3, one of the most important effectors of the PI3K/
AKT pathway, with mTOR stimulating protein synthesis
and initiating onset of the G1 phase of the cell cycle and
interacting with proteins that regulate apoptosis [17].
Germline loss of PTEN is the hallmark of Cowden
syndrome [18], while sporadic alterations in PTEN have
been observed in a broad spectrum of malignancies [19].
The multiple mechanisms that lead to PTEN inactiva-
tion render their study difficult; therefore, determining a
gene’s protein expression is considered a good way to
assess the functional status of the gene [20–22]. The
absence of expression is considered a reflection of inacti-
vation of the gene, independent of its cause.
The aim of this work was to determine the distribution
and inactivation frequency of PTEN in EC and AC of
GBC and to establish the correlation with clinical and
morphological parameters and survival. An additional
aim was to consider indirectly the importance that
PTEN inactivation may have in the deregulation of the
PI3K/AKT pathway in GBC.
Methods
Cases and controls
108 cases of primary gallbladder adenocarcinomas di-
agnosed in the Puerto Montt Regional Hospital and
the Temuco Diagnostic Center were included. In each
case, a representative inclusion of the tumor was se-
lected (anonymized archive material of formalin-fixed,
paraffin-embedded tissues). In all 108 cases, areas of
non-tumor mucosa adjacent to the neoplastic lesions
were used as an internal control. This work was ap-
proved by the Ethics Committee of the National Fund
for Scientific and Technological Development (FON-
DECYT) and that of the Faculty of Medicine of the
Clínica Alemana-Universidad del Desarrollo.
Immunohistochemical technique
The immunohistochemical study was performed on
complete histological sections, taking the lack of infor-
mation regarding the degree of heterogeneity of PTEN
protein expression in this and other neoplasias into
consideration. The standard automated immunohisto-
chemical technique for fixing tissue in formalin and
embedding it in paraffin was used. The 4-micron thick
histological sections were deparraffinized and hydrated
in decreasing alcohol concentrations. Antigens were
recovered by exposure to microwaves in citrate buffer
pH 6.0 and washed in PBS pH 7.4. The monoclonal
antibody PTEN (D4.3) (XP® Rabbit mAb Cell Signaling)
was used in a dilution of 1:125. The primary antibody
was incubated at room temperature for 60 min and
then incubated with the complex Super Picture Poly-
mer Detection Kit™ Zymed in a Dakoautostainer™. All
determinations were made in a single run to avoid vari-
ations in the assessment conditions.
Methods for measuring positivity
The immunohistochemical positivity was expressed by
means of cytoplasmic and nuclear staining with slight
membrane reinforcement in both the normal and tumor
cells. Positivity was estimated according to the following
scale used by other authors [22]: intensity 0 = (negative),
1 + (weak), 2+ (moderate or intense). Positivity percent-
age = 0 % (negative), > 1–100 % (positive). All the cases
included areas of non-tumor tissue. Positive staining
was measured based on a comparison between the non-
tumor mucosa and the tumor. Tests were also per-
formed with homologous scales that included factors
like staining intensity and an estimation of the percent-
age of positive cells [21]. The score obtained enabled
an ROC analysis to determine the greatest degree of
sensitivity and specificity of the immunohistochemical
staining [23]. However, there were no significant dif-
ferences in terms of the semi-quantitative estimation
initially described.
Sample determination
Given the limited available information regarding PTEN/
PI3K/AKT/mTOR alterations in GBC, an estimate was
made based on previous reports in other malignancies.
For most of the markers used, there is very little informa-
tion regarding patient survival. It was expected that a
20 % mutation frequency and altered immunohistochemi-
cal protein expression between 5 and 50 % of the cases
would be observed. Greater positivity was expected in
locally advanced tumors. In the control group (non-
tumor), it was expected that positivity of mutations or
abnormal expression would be found in less than 3 and
10 % of the cases, respectively. As an internal control,
adjacent non-tumor mucosa were included in all cases
where possible. The minimum sample size for analysis
was based on the number of predictors. In this study, the
markers were considered as each requiring at least ten
observations for analysis. The latter estimation provided a
final sample size of around 70 patients evenly distributed.
For a 95 % confidence interval with a corrected statistical
power of 95 %, a minimum of 70 cases and 50 controls
were required.
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Statistical analysis
This was done by means of a chi-squared test and
Fisher’s exact test for the contingency tables (p < 0.05)
as well as an analysis of variance for the averages and
Kaplan-Meier actuarial survival curves with a log-rank
test of significance.
Results
The group comprised 108 cases, the general character-
istics of which are summarized in Table 1. Eighty-four
percent of the cases were women with an average age
of 65.1 years (SD ± 11.6 years) and the remaining 17 were
men with an average of age of 66.1 years (SD ±10.1 years).
All the cases were adenocarcinomas. Thirty-five cases
(33 %) were EC (17 mucous carcinomas and 18 muscular
carcinomas) and 73 (67 %) were AC (29 subserosal carcin-
omas, 24 serosal, and 20 cases beyond the serosa). The
difference in the average ages between the early and
advanced carcinomas, as well as the relation between the
level of tumor infiltration of the wall and the progression
in the average ages was significant (p < 0.001). 30.3 % of
the tumors were well differentiated, with the great major-
ity being moderately differentiated (51.5 %) or poorly dif-
ferentiated (18.2 %).
The immunohistochemical staining in the 108 tumors
and their respective internal controls are summarized in
Table 2. In 96.3 % (104 cases) the non-tumor mucosa
showed moderate or intense positivity (2+) and only
3.7 % (4 cases) were weak positive (1+). No negative
cases were observed in this group. In the GBC, however,
three cases (2.8 %) had an absence of expression or in-
activation of PTEN (in the presence of positive internal
controls) (Fig. 1). All the cases without PTEN expression
were AC, all women (50, 56 and 62 years respectively),
one subserosal and two serosal with survival of 3, 6.2
and 9.9 months respectively after diagnosis. The inacti-
vation frequency in the AC patient group reached 4.1 %
(3 of 73 cases). Unlike what was observed in non-tumor
tissues, the adenocarcinomas had a similar proportion of
positivity (1+) or weak compared to a moderate or
intense positivity (2+), which could suggest a partial or
incomplete degree of PTEN activity.
Actuarial survival of the group was 41 % at 5 years of
follow-up. In the 73 patients with AC, the actuarial
survival at 10 months of follow-up was 52 and 29 % at
5 years. However, the three patients who presented
immunohistochemical inactivation of PTEN died before
the 10 months. Although the number is small and does
not permit a statistically valid conclusion, this fact is
noteworthy (Fig. 2).
Discussion
Our results show immunohistochemical expression of
PTEN protein in all the cases used as internal controls,
with this expression being moderate or intense from
the immunohistochemical point of view in 96.3 % of
the cases, which may reflect normal activity in this
gene. No negative cases were observed, which may sug-
gest some degree of PTEN inactivation in the non-
tumor mucosa adjacent to the tumors. However, in the
GBC there was a greater dispersion in the intensity of
the positive staining, being weak in 54.5 % of the cases
and moderate in 42.6 %, which may mean that the
tumor tissues present a variable expression, possibly a
reflection of differing degrees of PTEN activity or
Table 1 General features of gallbladder cancer patients
Age Number Year SD
Female 91 (84.3 %) 65.1 ±11.6
Male 17 (15.7 %) 66.1 ±10.1
Total 108 65.2 ±12.3
Mínimum 39 years Maximal 90 years



















Beyond serosa 20 18.1
108 100
Table 2 Intensity of immunohistochemical expression of PTEN
in non-tumor gallbladder mucosa and gallbladder cancer
Non-tumor mucosa Gallbladder cancer
Intensity Number Percent Number Percent
0 0 0 3 2,8
1 4 3,7 59 54,6
2 104 96,3 46 42,6
108 100 108 100
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inactivation. This being a recessive gene, inactivation of
an allele does not necessarily compromise its function
entirely, as it can express itself partially [24]. In most
tumors the loss of PTEN is monoallelic (gliomas,
breast, colon, lung), with biallelic being less frequent
[24–27], as inactivation due to methylation of promoter
areas is one of the inactivation mechanisms that occurs
more frequently than genomic alterations [24, 28, 29].
Thus, the absence of PTEN expression in three cases of
advanced GBC suggests is an infrequent phenomenon
(4.1 % of all AC) and is also delayed since its inactiva-
tion could not be demonstrated through the loss of its
expression in any of the 35 EC. There is little informa-
tion about the inactivation of this gene in GBC measured
using different molecular techniques. Some indicate in-
activation frequencies ranging between 0 and 5 %, but this
does not rule out that other PTEN inactivation mecha-
nisms may be at work [16]. On the other hand, the poor
prognosis of the three patients with an absence of PTEN
protein expression compared to patients at similar stages
must be pointed out [30]. In these patients, PTEN inacti-
vation may have released the PI3k/AKT pathway, which
through some of its effectors like mTOR is able to activate
cell proliferation [31]. Although PTEN inactivation is
observed in around 4 % of the advanced cancers, it is
worthy of note that the other inactivation mechanisms
in this proliferative pathway and which promote tumor
growth and development have recently been reported
in significant percentages (http://cancer.sanger.ac.uk,
[32–34]), which will open up important expectations
for the use of selective blockers and inhibitors of this
pathway as a targeted therapy in patients with advanced
Fig. 1 PTEN immunohistochemistry expression. a Strong cytoplasmic positive expression of PTEN in gallbladder adenocarcinoma. b Infiltrating
adenocarcinoma with negative PTEN expression in tumor cells and stromal and vascular positivity
Fig. 2 Survival and risk of death. Actuarial survival (left) and risk of death (right) curves in patients with advanced gallbladder cancer in relation to
the absence of expression of PTEN. The three patients with PTEN inactivation died prematurely compared to the advanced cancer patients
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gallbladder cancers [35–37]. Our recent work has
shown activating mutations in exons 9 and 20 of the
PI3k gene in 16.9 % of GBC, suggesting that this gene
together with PTEN could be a therapeutic target in
around 20 % of advanced gallbladder cancers (Roa et
al., observations not published).
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